Načítá se...
PCI-32765, the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
Ibrutinib is a potent covalent kinase inhibitor that targets BTK. BTK, or Bruton’s tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia. Ibrutinib has modest cytotoxicity again...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3584329/ https://ncbi.nlm.nih.gov/pubmed/23296407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11899-012-0147-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|